Comparative Pharmacology
Head-to-head clinical analysis: NOROXIN versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOROXIN versus ZAGAM.
NOROXIN vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg orally twice daily for 3-14 days depending on indication.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
10-12 hours; prolonged in renal impairment
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic